[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:fr":3},{"name":4,"total":5,"recruiting":5,"trials":6},"FRα",4,[7,15,22,28],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07059845","A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer",[11],"Phase 2","RECRUITING","2026-08-26T02:15:40.343619Z","2026-06-04T01:30:07.896241Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT07218809","AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer",[19],"Phase 3","2026-08-26T02:16:23.080181Z","2026-05-05T02:43:29.327362Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT04606914","Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer",[11],"2026-08-26T02:17:32.059863Z","2026-05-05T02:43:27.132670Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT06365853","A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression",[11],"2026-08-03T02:14:57.006298Z","2026-04-29T02:57:57.157665Z"]